| 复发难治性弥漫大B细胞淋巴瘤的生物靶向治疗 |
| |
| 引用本文： | 刘宁. 复发难治性弥漫大B细胞淋巴瘤的生物靶向治疗[J]. 白血病．淋巴瘤, 2016, 25(5): 317-320. DOI: 10.3760/cma.j.issn.1009-9921.2016.05.018 |
| |
| 作者姓名： | 刘宁 |
| |
| 作者单位： | 安徽医科大学附属省立医院血液内科, 合肥,230001 |
| |
| 摘 要： | 含有利妥昔单抗的化疗方案能改善弥漫大B细胞淋巴瘤(DLBCL)患者的预后,然而仍有部分患者在一线应用R-CHOP方案后转为复发难治性DLBCL(RR-DLBCL),且预后不良.对DLBCL及其相关肿瘤基因表达研究证实基因水平的生物靶向治疗能改善RR-DLBCL患者的预后.目前,一些新的靶向治疗成为研究热点.文章就RR-DLBCL的生物靶向治疗进展进行综述.
|
| 关 键 词： | 淋巴瘤,大B-细胞,弥漫性 复发 难治 |
Biological targeted treatment of refractory / relapsed diffuse large B-cell lymphoma |
| |
| Abstract: | Diffuse large B-cell lymphoma (DLBCL) is the aggressive non-Hodgkin's lymphoma.Rituximab in combination with chemotherapy had improved the outcomes,however,a substantial proportion of these patients transfer into refractory or eventually relapsed lymphoma after using R-CHOP as a front-line treatment regimen with poor prognosis.With the research development on DLBCL and its related gene,it is confirmed that gene biological targeted therapy can improve the prognosis of patients with refractory /relapsed DLBCL (RR-DLBCL).Recently,some new targeted therapies become research hotspots.This review will focus on recent development and future direction of biological targeted treatment in RR-DLBCL. |
| |
| Keywords: | Lymphoma,large B-cell,diffuse Relapsed Refractory |
| 本文献已被 万方数据 等数据库收录！ |
|
